Novartis pursues PBS listing for Beovu  

Novartis is working to ensure its newly-approved drug Beovu is accessible via the Pharmaceutical Benefits Scheme (PBS) at the earliest opportunity after expressing disappointment over an initial decision not to recommend it for the government-subsidised medicines program. Read more

© All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited